Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03753919
Title Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY)
Acronym DUTHY
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Grupo Espanol de Tumores Neuroendocrinos
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP

Facility Status City State Zip Country Details
Instituto Catalán de Oncología de Hospitalet L'Hospitalet de Llobregat Barcelona 08908 Spain Details
Hospital Provincial de Castellón Castelló Valencia Spain Details
Hospital Clínic Barcelona Barcelona Spain Details
Hospital Universitari Vall d'Hebron Barcelona Spain Details
MD Anderson Cancer Center Madrid 28033 Spain Details
Hospital Clínico San Carlos Madrid Spain Details
Hospital Universitario 12 de Octubre Madrid Spain Details
Hospital Universitario HM Sanchinarro Madrid Spain Details
Hospital Universitario La Paz Madrid Spain Details
Hospital Universitario Ramón y Cajal Madrid Spain Details
Hospital General Universitario Morales Meseguer Murcia Spain Details
Hospital Universitario Virgen de la Victoria Málaga Spain Details
Clínica Universidad de Navarra Pamplona Spain Details
Instituto Valenciano de Oncología Valencia 46009 Spain Details
Complejo Hospitalario Universitario de Vigo (CHUVI) Vigo 36036 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field